Company Filing History:
Years Active: 1992-2001
Title: Lillian Anne Bell: Innovator in Biopharmaceuticals
Introduction
Lillian Anne Bell is a prominent inventor based in Seattle, WA, known for her significant contributions to the field of biopharmaceuticals. With a total of nine patents to her name, she has made remarkable advancements in the development of ligand-binding polypeptide fusions and methods for producing biologically active peptide dimers.
Latest Patents
Among her latest patents is the invention of ligand-binding, dimerized polypeptide fusions. This innovation involves two polypeptide chains, each containing a ligand-binding domain of either a growth factor receptor or a hormone receptor, which are joined to an immunoglobulin constant region polypeptide. The dimerization of these polypeptide fusions enhances their biological activity. Another notable patent focuses on methods for producing secreted ligand-binding fusion proteins. This method utilizes a DNA sequence encoding a receptor analog or a peptide that requires dimerization for biological activity, which is joined to a dimerizing protein. These polypeptides can be used to determine the presence of and purify human PDGF or its isoforms.
Career Highlights
Lillian is currently employed at Zymogenetics, Inc., where she continues to push the boundaries of biopharmaceutical research. Her work has been instrumental in developing innovative solutions that address critical health challenges.
Collaborations
Throughout her career, Lillian has collaborated with esteemed colleagues, including Andrzej Z Sledziewski and Wayne R Kindsvogel. These partnerships have fostered a collaborative environment that enhances the research and development of new biopharmaceuticals.
Conclusion
Lillian Anne Bell's contributions to the field of biopharmaceuticals through her innovative patents and collaborative efforts highlight her as a leading figure in the industry. Her work continues to pave the way for advancements in medical science and therapeutic solutions.